Ethics approval to undertake a study of medicinal cannabis in sufferers of post-traumatic stress disorder (PTSD) has been received by Australian company, Applied Cannabis Research.
PTSD is a particular set of reactions that can develop in people who have experienced a traumatic event that threatened their life or safety. As a result, sufferers develop feelings of intense fear, helplessness and horror. It is estimated PTSD affects 12 per cent of Australians.
Patient recruitment for the landmark year-long trial will be facilitated by the Cannabis Access Clinics network.
Participants in the study will receive medicinal cannabis extract ECs315 from product supplier BOD Australia, the company that successfully trialled delivery of cannabidiol (CBD) into a patient’s bloodstream using a sublingual wafer system.
Patients will bear standard treatment costs for participating in the study, although they will be eligible for rebates through Medicare and, in some cases, private insurers.
Patients interested in being assessed for eligibility in the study can contact Cannabis Access Clinics on 1300 991 477 or email info@caclinics.com.au
